Three International Drug Developers Award $3.6 Million in Thorough QT Studies to eResearchTechnology
10 February 2005 - 8:05AM
PR Newswire (US)
Three International Drug Developers Award $3.6 Million in Thorough
QT Studies to eResearchTechnology Sponsors Include a Top-10 Pharma
and Two Japan-based International Pharmaceuticals Demonstrating
Continued Global Adoption of Regulatory Guidance PHILADELPHIA, Feb.
9 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT)
(NASDAQ:ERES), a leading provider of centralized
electrocardiographic (ECG) collection and interpretation services,
announced today that it has been awarded three Thorough QT studies
valued at more than $3.6 million in cardiac safety monitoring and
services from a global top-10 drug developer and two Japan-based
international drug developers for three compounds in clinical
trials. The awards cover three significant Thorough QT studies, for
which eRT is providing comprehensive support, including provision
of digital 12-lead ECG equipment designed to facilitate collection
of cardiac safety data that is subsequently provided to eRT for
analysis. eRT will perform digital collection, measurement,
interpretation, review, and distribution of cardiac safety data
through its EXPeRT(R) workflow enabled data handling technology,
the first solution in production that was designed explicitly to
meet emerging international regulatory guidance and technical
standards. "We are excited to have been selected to perform cardiac
safety services for these trials, which illustrate how the adoption
of evolving regulatory guidance is cutting across all segments and
geographies of the new drug development industry," said Scott
Grisanti, senior vice president of business development and chief
marketing officer at eRT. "eRT is unique in its ability to provide
the overall capacity and throughput required to address the demands
of big pharma's robust pipelines, while also being able to provide
consultative services and turnkey solutions required by emerging
growth companies like the Japanese sponsors for two of these
important studies." Based in Philadelphia, PA, eResearchTechnology,
Inc. (http://www.ert.com/) is a provider of technology and services
to the pharmaceutical, biotechnology and medical device industries
on a global basis. The company is a market leader in providing
centralized core-diagnostic electrocardiographic (ECG) technology
and services to evaluate cardiac safety in clinical development.
The company is also a leader in providing technology and services
to streamline the clinical trials process by enabling its customers
to automate the collection, analysis, and distribution of clinical
data in all phases of clinical development. Statements included in
this release may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as
competitive factors, technological development, market demand, and
the company's ability to obtain new contracts and accurately
estimate net revenues due to variability in size, scope and
duration of projects, and internal issues in the sponsoring client.
The sponsors may cancel these agreements at their sole discretion.
As a result, actual results may differ materially from any
financial outlooks stated herein. Further information on potential
factors that could affect the company's financial results can be
found in the company's Reports on Forms 10-K and 10-Q filed with
the Securities and Exchange Commission. DATASOURCE:
eResearchTechnology, Inc. CONTACT: Joan Sterlacci,
eResearchTechnology, Inc., +1-908-203-6473; or Matt Hayden, Hayden
Communications, +1-858-456-4533, for eResearchTechnology Web site:
http://www.ert.com/
Copyright
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jun 2024 to Jul 2024
East Resources Acquisition (NASDAQ:ERES)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about East Resources Acquisition Company (NASDAQ): 0 recent articles
More Eresearch Tech (MM) News Articles